On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Stocks To Buy Now

Blog


ORHub Inc. (ORHB) on a Mission to Optimize the Business of Surgery

  • Data analysis enables increased effectiveness, reduced costs and better outcomes for both surgeons and patients
  • ORHub recently announced a stay of litigation as it works toward settlement of a contract litigation

ORHub Inc.’s (OTC: ORHB) Surgical Spotlight(R) cloud-based analytics tool for use in operating rooms is bound to optimize and transform the surgical business, as the company’s chief executive officer, Dr. Robert Lazzara, said in an exclusive interview with NetworkNewsAudio (http://ibn.fm/toHZi).

The product allows administrators, surgeons and nurse leaders to make better decisions for the operating room on the basis of relevant data analysis. Surgical Spotlight(R) takes data feeds from the operating room information system and produces a functional dashboard aimed at identifying improvement opportunities. Beyond ensuring more effective operations, ORHub aims to deliver a solution that’s capable of reducing costs but also reliable in terms of improving outcomes for both patients and surgeons, Lazzara explained.

According to Lazzara, the introduction of such data-driven solutions could promote a health care transformation in the future. “By providing the information that allows for a change in behavior, control is put into the hands of surgeons and administrators, enabling the evaluation of trends, and empowering the facility to make instantaneous adjustments that will continue building efficiency and profitability on an ongoing basis,” he said.

ORHub is on a mission to maximize exposure, secure capital and drive revenue. At the same time, increasing awareness is expected to play a vital role in the widespread adoption of Surgical Spotlight(R). Empowerment through mentorship across the country could easily contribute to a paradigm shift that will eventually ensure modernization across the health care surgical service provision sector, Lazzara added.

ORHub’s mission is to place Surgical Spotlight(R) into as many operating rooms as possible. Currently, the company is relying on video streaming and digital platforms to increase awareness among both surgical team leaders and patients.

Since its launch in 2019, Surgical Spotlight(R) has continued gaining market traction and penetration. Right now, procedurally oriented specialties include the interventional cardiology lab, gastrointestinal lab and interventional radiology lab.

In other news, ORHub recently announced that it has negotiated a stay of litigation and is working toward a settlement (http://ibn.fm/oY1nm).

ORHub is a growth-stage data analytics company that aims to optimize surgical processes through lean process improvement. A Microsoft Silver Partner, the company utilizes the Azure cloud to help customers fully benefit from all data captured in the operating room.

Through its strategic work, ORHub has secured a number of crucial partnerships, like those with the Hoag Orthopedic Institute in the Province network, Anderson Regional Medical Center, Baptist Health in Jacksonville, Alvarado Hospital Medical Center in the Prime Network and Orthopedic Institute Surgery Center in the SMP network.

ORHub has presented Surgical Spotlight(R) at multiple events and conferences in 2019. The company has secured approval to present at nursing forums and offer 1.2 contact hours toward Continuing Education Units from Terri Goodman, RN, PhD, & Associates.

For more information, visit the company’s website at www.ORHub.com

NOTE TO INVESTORS: The latest news and updates relating to ORHB are available in the company’s newsroom at  http://ibn.fm/ORHUB

From Our Blog

Longeveron Inc. (NASDAQ: LGVN) Discusses 2023 Progress and 2024 Plans in Corporate Update

March 28, 2024

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing regenerative medicine for life-threatening conditions with unmet medical needs, recently released its full-year results for the period ended December 31, 2023, and provided a corporate update (https://ibn.fm/iORBu). Results from multiple studies using Longeveron’s lead investigational therapeutic candidate, Lomecel-B(TM), were announced by the company last year. “In 2023 […]

Rotate your device 90° to view site.